Publication | Closed Access

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Supplementary ResultsEndocrine OncologyBreast OncologyOncologyMedicineClinical TrialsGynecologyCentrally-assessed Erbb2 StatusBreast CancerPharmacotherapyMenopauseMenopause Hormone TherapyPharmacologyGynecology OncologyEndocrine-related CancerWomen's HealthPostmenopausal Women